Показать сокращенную информацию
dc.contributor.author | Kostianets O. | |
dc.contributor.author | Shyyan M. | |
dc.contributor.author | Antoniuk S. | |
dc.contributor.author | Filonenko V. | |
dc.contributor.author | Kiyamova R. | |
dc.date.accessioned | 2018-09-19T21:14:33Z | |
dc.date.available | 2018-09-19T21:14:33Z | |
dc.date.issued | 2017 | |
dc.identifier.issn | 1354-750X | |
dc.identifier.uri | https://dspace.kpfu.ru/xmlui/handle/net/143670 | |
dc.description.abstract | © 2016 Informa UK Limited, trading as Taylor & Francis Group.Content: Identification of panel of SEREX-defined antigens for breast cancer autoantibodies profile detection. Objective: To create panel of antigens that can differentiate breast cancer patients and healthy individuals. Methods: SEREX (serological analysis of cDNA expression libraries) method, ELISA (enzyme-linked immunosorbent assay), qPCR (quantitative polymerase chain reaction). Results: In large-scale screening of 16 SEREX-antigens by sera of breast cancer patients and healthy donors, a combination of six antigens (RAD50, PARD3, SPP1, SAP30BP, NY-BR-62 and NY-CO-58) was identified, which can differentiate breast cancer patients and healthy donors with 70% sensitivity and 91% specificity. Elevated mRNA expression of SPP1 gene was revealed in breast tumors (2–7-fold) that correlated with SPP1 antigen immunoreactivity in autologous patients’ sera. Conclusions: The new panel of six SEREX-antigens was proposed, which enables creation of serological assay for breast cancer diagnostics and/or prognosis. | |
dc.relation.ispartofseries | Biomarkers | |
dc.subject | antigenic panel | |
dc.subject | autoantibody | |
dc.subject | breast cancer | |
dc.subject | Tumor-associated antigens | |
dc.title | Panel of SEREX-defined antigens for breast cancer autoantibodies profile detection | |
dc.type | Article | |
dc.relation.ispartofseries-issue | 2 | |
dc.relation.ispartofseries-volume | 22 | |
dc.collection | Публикации сотрудников КФУ | |
dc.relation.startpage | 149 | |
dc.source.id | SCOPUS1354750X-2017-22-2-SID84994890034 |